Table 2.

Patient characteristics (n = 52)

Characteristic	Mean (SD)*
Age (years)	65 (12)
Male [n (%)]	41 (79)
Weight (kg)	98 (23)
Height (m)	1.75 (0.08)
BMI (kg m−2)	31.8 (7.1)
BSA (m2)	2.17 (0.28)
Estimated GFR [ml min−1 (1.73 m2)−1]	72 (13)
Estimated GFR (ml min−1)	91 (23)
CHA2DS2-VASc	2.5 (1.7)
HAS-BLED	1.0 (1.0)
Dabigatran etexilate dose rate
75 mg twice daily [n (%)]	3 (6)
110 mg twice daily [n (%)]	24 (46)
150 mg twice daily [n (%)]	25 (48)

Abbreviations are as follows: BMI, body mass index; BSA, body surface area; GFR, glomerular filtration rate; CHA₂DS₂-VASc and HAS-BLED are scoring systems for assessing thromboembolic and haemorrhagic risk, respectively, in the setting of atrial fibrillation 23,24.

^*Unless stated otherwise.